S
74.05
-0.27 (-0.36%)
| 前收盘价格 | 74.32 |
| 收盘价格 | 75.34 |
| 成交量 | 561,523 |
| 平均成交量 (3个月) | 1,096,580 |
| 市值 | 6,430,595,072 |
| 价格/销量 (P/S) | 650.22 |
| 股市价格/股市净资产 (P/B) | 10.65 |
| 52周波幅 | |
| 利润日期 | 4 Aug 2026 |
| 稀释每股收益 (EPS TTM) | -3.06 |
| 总债务/股东权益 (D/E MRQ) | 0.06% |
| 流动比率 (MRQ) | 8.06 |
| 营业现金流 (OCF TTM) | -169.86 M |
| 杠杆自由现金流 (LFCF TTM) | -68.57 M |
| 资产报酬率 (ROA TTM) | -25.34% |
| 股东权益报酬率 (ROE TTM) | -65.82% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 看涨 | 混合的 |
| Biotechnology (全球的) | 看涨 | 混合的 | |
| 股票 | Spyre Therapeutics, Inc. | 看跌 | 看跌 |
AIStockmoo 评分
-1.6
| 分析师共识 | -2.0 |
| 内部交易活动 | NA |
| 价格波动 | -5.0 |
| 技术平均移动指标 | 0.0 |
| 技术振荡指标 | 0.5 |
| 平均 | -1.63 |
|
Spyre Therapeutics Inc is a biotechnology company that aims to create the next-generation of inflammatory bowel disease (IBD) products by combining antibody engineering, rational therapeutic combinations, and precision medicine approaches for patient selection. IBD is a chronic condition characterized by inflammation within the gastrointestinal tract, including two main disorders which are UC and CD. It has a single reportable segment, which is the development of biopharmaceutical products for the treatment of patients with IBD and other immune-mediated disease. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Value |
| 内部持股比例 | 8.71% |
| 机构持股比例 | 106.07% |
该时间范围内无数据。
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合